ANXA5 and neoplasm: Interestingly, treatment with AnxA5 resulted in the generation of slightly stronger systemic and tumor-infiltrating E7-specific CD8+ T cell responses compared to treatment with other checkpoint inhibitors (Fig. 4d, e).